Opinion

Video

Factors Driving 3L Therapeutic Selection for mCRC

Author(s):

John Marshall, MD,Al B. Benson III, MD, FACP, FACCC, FASCO

Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).

  1. Dr Marshall to Panel:Please outline your approach to treatment selection for patients with mCRC in the 3L setting and discuss factors influencing your choice of therapy.
    1. Dr Cohen: In which patients would you consider fruquintinib versus TAS-102 ± bevacizumab?
      1. Dr Marshall: For which patients would you deviate from this approach and why you might make this decision?

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Squamous cell anal carcinoma | Image Credit: © Anatomy Insider - stock.adobe.com
December 20th 2024

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
December 18th 2024

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Michael J. Pishvaian, MD, PhD, director, Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, associate professor of Oncology, Johns Hopkins Medicine
December 13th 2024

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management

FDA
December 4th 2024

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma